The trial will assess the time-to-relief in patients suffering from breakthrough cancer pain.Â Based on its clinical data, Tetra believes that the pharmacodynamic properties of PPP001 may provide a novel faster acting alternative to the opioid fentanyl.Â In addition, the time-to-maximal plasma concentrations of THC suggest that PPP001 will provide rapid relief to the patientâ€™s suffering. Â As a prescription drug with a Drug Identification Number